Use of continuous glucose monitoring among children and young adults with type 1 diabetes nearly doubled from 2017 to 2020 in the U.S. from 25% to 49% and was associated with lower HbA1c for users vs. non-users, according to registry data. The rate of CGM use among U.S. residents younger than 25 years remained less than that of their European peers, who saw an increase in use from 40% to 76%